Nemolizumab 30MG injectable pens - QTY. 16
Ended Awarded Last action
- Contract number
- 36C26126N0187
- Awardee
-
Galderma Laboratories, L.P. UEI MNX4XY6QXEL3
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $33,920
Award facts
- Contract value 100% obligated
- $33,920.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dallas, TX 75201, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$15,891 | |
| Original award | $49,811 |
About this award
Galderma Laboratories, L.P., a pharmaceutical manufacturer headquartered in Dallas, Texas, was awarded a delivery order on October 30, 2025, to supply 16 units of Nemolizumab 30mg injectable pens to the Department of Veterans Affairs' Veterans Integrated Service Network 21 (VISN 21). This contract, valued at $33,920, operates under a firm fixed-price arrangement with no set-aside designation and an ultimate completion date of February 6, 2026. The delivery order falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), representing a modification to reduce the unit price for the injectable pharmaceutical product.
This award reflects Galderma Laboratories' established specialization as a primary supplier of injectable pharmaceutical products to the VA healthcare system. The company has maintained continuous federal contractor registration since February 2002 and has received multiple awards from various Veterans Integrated Service Networks over the past year, with individual contract values ranging from approximately $3,063 to $49,811. The short-term performance period typical of pharmaceutical delivery orders underscores the time-sensitive nature of supplying medications to support VA patient care operations. The contract is being performed in Dallas, Texas, where the contractor is located, with Galderma Laboratories serving as the prime awardee and no subcontractors identified.
Quick answers
Who was awarded contract 36C26126N0187?
36C26126N0187 was awarded to Galderma Laboratories, L.P. by Veterans Integrated Service Network 21 (Veterans Health Administration) on October 30, 2025.
How much is contract 36C26126N0187 worth?
The government has obligated $33,920 on 36C26126N0187.
Is contract 36C26126N0187 an order under another contract?
Yes. 36C26126N0187 is a delivery order under V797D70255, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26126N0187 competed?
The extent of competition for 36C26126N0187 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award